ReNeuron Receives DSMB Clearance to Progress to Higher Dose in Stem Cell Clinical Trial in Disabled Stroke Patients: First Patient Treated in this Higher Dose Cohort
August 14, 2012 - (ReNeuron) - "ReNeuron provides an update on progress with the PISCES clinical trial of its ReN001 stem cell therapy for disabled stroke patients. In this open label, dose-ranging Phase I safety study, taking place in Scotland, ReNeuron’s ReN001 stem cell therapy is being administered in ascending doses to a total of 12 stroke patients who have been left disabled by an ischaemic stroke, the most common form of the condition." Read Full Article
